Efficacy and clinical data

The efficacy of VENCLEXTATM monotherapy was established based on overall response rate in a phase 2, open-label, single-arm, multicenter clinical trial of 106 in previously treated CLL patients with 17p deletion. 1 Patients received VENCLEXTA via a weekly ramp-up schedule starting at 20 mg ramping to 50 mg, 100 mg, 200 mg to 400 mg once daily until disease progression or unacceptable toxicity. The median time on treatment at the time of evaluation was 12.1 months (range: 0 to 21.5 months). 1

ORR, time to first response, and DoR

Minimal residual disease